Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer
A meta-analysis of randomized controlled trials
Cuiying Wang, MD, Xiaohua Liu, BD, Xiaohua Wang, BD, Yanlei Wang, BD, Na Cha, BD

Abstract
To comparatively evaluate chemoradiotherapy (CRT) and chemotherapy (CT) for the treatment of locally advanced pancreatic cancer (LAPC) by meta-analysis.

A literature search was performed until August 2016 to identify comparative studies assessing survival rates and complications. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were determined with the fixed or random effects model.

Five randomized controlled trials (RCTs) met the defined inclusion criteria. A total of 593 patients were included, with 295 and 298 treated with CRT and CT, respectively. Overall survival showed no statistically significant difference in patients treated with CRT and CT at 6, 12, 18, and 24 months (respectively: OR = 1.13, 95% CI: 0.60–2.17; OR = 1.15, 95% CI: 0.53–2.52; OR = 1.13, 95% CI: 0.43–2.95; OR = 1.07, 95% CI: 0.67–1.72). Meanwhile, CRT had higher rates of grade 3 to 4 adverse events (nausea and vomiting, OR = 2.74, 95% CI: 1.36–5.52; diarrhea, OR = 4.28, 95% CI: 1.16–15.71). The data are not sufficient to change from CT to CRT in the treatment of patients with LAPC and thus clinical discretion is required until more data is accumulated.

Abbreviation: 5-FU = 5-fluorouracil, 95% = CI 95% confidence intervals, CNKI = China National Knowledge Internet, CRT = chemoradiotherapy, CT = chemotherapy, FOLFIRINOX = 5-FU, leucovorin, irinotecan and oxaliplatin, GEMOX = Gemcitabine, oxaplatin, IMRT = intensity-modulated radiotherapy, LAPC = locally advanced pancreatic cancer, OR = odds ratios, PC = pancreatic cancer, RCT = randomized controlled trial, RRS = robotic radiosurgery, SBRT = stereotactic body radiotherapy.

Keywords: chemoradiotherapy, chemotherapy, local advanced pancreatic cancer, meta-analysis

1. Introduction
Pancreatic cancer (PC) is the 4th leading cause of cancer-related death in the United States, and is expected to become 2nd by 2030. The American Cancer Society estimated that 53,070 (27,670 men and 25,400 women) individuals would be diagnosed with pancreatic cancer in 2016, with 41,780 (27,670 men and 25,400 women) individuals would succumbing to the disease.[1] Epidemiological data in Europe reveal that PC is the 6th most prevalent cancer and the 5th leading cause of cancer related death, with yearly 70,000 estimated deaths. PC incidence has increased in recent decades, possibly due to elevated prevalence of obesity, aging, and unknown factors.[2] At initial diagnosis, 50% of patients present with metastatic disease while 30% have locally advanced tumors; therefore, only 20% of cases are resectable.[3]

The management of locally advanced pancreas cancer (LAPC) is fraught with difficulties because of the tantalizing goal shared by patients and clinicians that conversion to a resectable cancer can be achieved with favorable response to intensive induction treatment. Surgeons cannot remove tumors that encase the aorta, obliterate the superior mesenteric vein, or involve more than 180° of the superior mesenteric artery or celiac vessels, achieving negative tumor margins. In this context, surgery is not advised due to the associated morbidity and improbability of cure. In unusual circumstances, intensive treatment with chemotherapy (CT) and/or radiation therapy has the potential to convert unresectable to resectable lesions. This possibility, albeit remote, and the categorization of some tumors as borderline resectable motivate the search for strategies to achieve pronounced responses to chemotherapy or radiation therapy necessary to make surgery feasible.[4]

The role of radiation therapy in the management of LAPC remains controversial. In the early 1980s, fluorouracil-based concomitant chemoradiotherapy (CRT) was shown to be better compared with radiotherapy alone.[5] In the late 1990s, gemcitabine was adopted as the preferred treatment strategy, replacing CRT, in patients with LAPC. In addition, 7 randomized trials of LAPC patients comparing CRT with CT yielded contradictory data.[6–12]
The purpose of this study was to comparatively evaluate the effects of CRT and CT in patients with LAPC.

2. Methods

2.1. Literature review
A systematic review of the MEDLINE, Embase, Cochrane center, China National Knowledge Internet (CNKI), and WanFang databases was performed from inception to August 2016, using the following keywords and combinations: [“PC (MeSH) or PC (Text word)”] and [“antineoplastic agents (Text word) or chemotherapy (MeSH) or chemotherapy (Text word) or chemoradiotherapy (Text word)”] and “clinical trials (Text word).” In addition, reference lists of the selected trials were screened for other relevant studies. Only English and Chinese languages were included. In addition to full-text publications, we also screened relevant reviews and meta-analyses of CRT in PC.

2.2. Data extraction and quality assessment
Data were extracted by 3 independent investigators using standardized forms. The recorded data included the number of patients, overall survival rates and complications. The quality of the selected articles was evaluated based on the nonrandomized controlled clinical trial quality evaluation standard.

2.3. Study selection criteria
Inclusion criteria for this study were: assessment of patients with a diagnosis of LAPC; prospective randomized controlled trial (RCT); both blinded and nonblinded studies were included; treatment with CT or CRT therapy.

2.4. Exclusion criteria
Abstracts, letters, editorials and expert opinions, reviews without original data, case reports, and studies lacking control groups were excluded. The following studies were also excluded: nonrandomized trials; inclusion of patients with metastatic disease or after resection surgery; trials with 2 separate cancer types, which did not report pancreatic data separately; no available survival data; treatment with radiation therapy alone.

2.5. Statistical analysis
The current meta-analysis was performed with the RevMan 5.3.0 software package. Odds ratios (ORs) or mean differences with 95% confidence intervals (95% CIs) were calculated for dichotomous and continuous outcomes, respectively. Random- and fixed-effects models were used with the “intention-to-treat” analysis. If results were similar between the 2 models, the random-effects model was reported, as it is commonly used for indirect comparisons. If results differed between the 2 models, both results were reported. Heterogeneity was explored by $\chi^2$ and $I^2$. $I^2 < 25\%$ and $I^2 > 50\%$ reflected small and large inconsistencies, respectively. $P < .05$ was considered statistically significant.

2.6. Publication bias
A funnel plot was used to explore bias. Asymmetry in the funnel plot of trial size against the treatment effect was used to assess the risk of bias.

2.7. Ethics
Since this article is based on meta-analysis of literature search, it does not involve ethics.

3. Results

3.1. Description of studies
A total of 7 studies meeting the inclusion criteria were identified.[6–12] However, there is currently no clear definition of LAPC, and some eligible gastric carcinoma patients had liver metastases in Hazel’s report.[6] Therefore, we believed there may be metastatic PC cases, and decided to exclude this article. According to the AJCC cancer staging manual, stage IV cases have distant metastasis; hence we also excluded Lin’s study.[11] Eventually, 5 RCTs[7–10,12] were included in the meta-analysis. Of 593 patients assessed in 5 studies, 295 and 298 were allocated to the CRT and CT groups, respectively, to evaluate their therapeutic effects on LAPC. Patient characteristics and evaluation indices are shown in Tables 1–3.

3.2. Overall survival rates
Six-month survival rates: A meta-analysis of 4 trials reporting these data showed that there was no significant difference between the 2 groups [OR = 1.13, 95% CI: 0.60–2.17; $P = .71$], and no evidence of significant heterogeneity (Table 4).

Twelve-month survival rates: A meta-analysis of 4 trials reporting these data showed that there was no statistically significant difference between the 2 groups [OR = 1.15, 95% CI: 0.53–2.52; $P = .73$], with certain heterogeneity.

Eighteen-month survival rates: A meta-analysis of 4 trials reporting these data showed that there was no statistically significant difference between the 2 groups [OR = 1.13, 95% CI: 0.43–2.95; $P = .87$], with certain heterogeneity.

Twenty-four-month survival rates: A meta-analysis of 5 trials reporting these data showed that there was no statistically significant difference between the 2 groups [OR = 1.07, 95% CI: 0.67–1.72; $P = .77$], with no evidence of heterogeneity (Fig. 1).

3.3. Grade 3 to 4 adverse events
Nausea and vomiting: A meta-analysis of 4 trials reporting these data showed that CRT resulted in significantly higher rates than the control CT [OR = 2.74, 95% CI: 1.36–5.52; $P = .005$], with certain heterogeneity.

Diarrhea: A meta-analysis of 4 trials reporting these data showed that the experimental (CRT) group had a significantly higher rate than the control (CT) group [OR = 4.28, 95% CI: 1.16–15.71; $P = .03$], with no evidence of heterogeneity.

3.4. Stratified analysis
We conducted a stratified analysis by sample size and chemotherapy included gemcitabine.

Chemotherapy included gemcitabine: A meta-analysis of 3 trials reporting overall survival rates showed that there was no statistically significant difference between the 2 groups at 12 and 24 months (respectively: OR = 0.91, 95% CI: 0.42–1.98; OR = 1.03, 95% CI: 0.62–1.70), with no evidence of heterogeneity. The experimental (CRT) group had a significantly higher nausea rates than the control (CT) group (OR = 3.37, 95% CI: 1.50–7.56; $P = .003$), with no evidence of heterogeneity.

Due to heterogeneity in sample size, sensitivity analyses were conducted using the 4 small trials. The subgroup analysis showed...
that there was no statistically significant difference between the 2 groups at 24 months (OR = 1.08, 95% CI: 0.46–2.54; \( P = .86 \)), with no evidence of heterogeneity. There was no statistically significant difference between the 2 groups at 12 months (OR = 1.34, 95% CI: 0.35–5.11; \( P = .66 \)), with no evidence of heterogeneity. The experimental (CRT) group had a significantly higher nausea rates than the control (CT) group (OR = 2.20, 95% CI: 1.05–4.62; \( P = .04 \)), with no evidence of heterogeneity.

3.5. Sensitivity analysis and publication bias

Publication bias may exist when no significant findings remain unpublished, thus artificially inflating the apparent magnitude of an effect.

Complications and overall survival rates following CRT or CT for LAPC treatment were determined by the random-effects models.

Funnel plot of the study results is shown in Figure 2. The funnel plot for 24-month overall survival rate following CRT or CT for LAPC treatment showed asymmetry, which suggested some publication bias.

4. Discussion

As shown in our current meta-analysis: the CRT group was not superior to the CT group in 6-, 12-, 18-, 24-month survival rates; the CRT group had significantly more grade 3 to 4 treatment-related adverse events than the CT group. At the same time, the results of further stratification analysis are similar.

Many centers currently consider locally advanced tumors as cancers with no distant metastasis, the absence of blood flow through the SMV and/or portal vein lumen, or venous involvement not amenable to reconstruction, involvement of the common hepatic artery or superior mesenteric artery over \( 180^\circ \) of the vessel circumference, any celiac abutment or aortic or inferior vena cava invasion or encasement. However, there is not standardized definition of LAPC in early stage.\(^{[13]}\) LAPC has been diagnosed by laparotomy for three decades. However, current diagnosis mainly depends on the imaging technology. Meanwhile, with advances in surgical techniques, the definition of LAPC is also changing.

As shown in early clinical practice, conventional radiotherapy for LAPC often cannot improve treatment efficacy. Three-dimensional conformal radiotherapy, intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and robotic radiosurgery (RRS) improve the therapeutic effectiveness. IMRT splits a typical radiation treatment field into smaller “beamlets.” It is implemented as dynamic IMRT (collimating leaves move in and out of the radiation beam path during treatment) or “step and shoot” IMRT (leaves change the field
shape while the machine is off). The cumulative effect is that the prescription dose conforms around the delineated target volumes, significantly reducing the doses reaching adjacent normal tissues.\[14,15\] SBRT can employ many of the same strategies, and is coupled with a high degree of anatomic targeting accuracy and reproducibility with high doses of ionizing radiation. This maximizes the cell-killing effect on the target while minimizing injury to adjacent normal tissues.\[16,17\] RRS is a particular SBRT technique. It is based on the delivery of a single large radiation fraction using a robotic linear accelerator. The reduced volume of irradiated normal tissue achieved by improving the treatment precision allows the delivery of a single radiation fraction (with RRS), which can potentially ablate all tissues in the treated area.\[18\]

The chemotherapy types and dosages administered concurrently with radiation therapy were also different in these trials. The standard of chemotherapy has also changed in the last few years in the treatment of LAPC. The nucleoside analogs

| Table 2 |
| Treatment of the included articles. |
| --- |
| **Opening treatment time** | **Treatment programs** |
| Klassen DJ, 1985 | 20 days postsurgery requiring resection and 14 days postsurgery requiring only laparotomy and biopsy and within 6 weeks after surgery | Chemotherapy: 5-FU 600 mg/m² weekly |
| Gastrointestinal Tumor Study Group, 1988 | Within 1 week of randomization and within 6 weeks of surgery. | Chemoradiotherapy: 40 Gy over 4 weeks plus 5-FU 600 mg/m² on the first 3 days of therapy and then 5-FU 600 mg/m² starting day of completion of radiation |
| Chauffert B, 2008 | Unstated | Chemotherapy: gemcitabine 1000 mg/m² weekly for 7 weeks and then 1000 mg/m² 3 weeks every 4 weeks. |
| Loehrer PJ, 2011 | Unstated | Chemoradiotherapy: 50.4 Gy (1.8 Gy × 5 days every week for 5.5 weeks) with gemcitabine 600 mg/m² beginning the first day of radiation and then weekly while getting radiation, followed by gemcitabine 1000 mg/m² weekly 3 weeks on and 1 week off × 5 cycles. |
| Hammel P, 2016 | After 4 months of induction chemotherapy | Chemoradiotherapy: gemcitabine 1000 mg/m² infusion weekly for 3 weeks, followed by a 1-week rest (1 cycle), for 2 cycle; with or without erlotinib 150 mg/day for a total of 2 months. |

| Table 3 |
| Characteristics of included articles. |
| --- |
| **No. of patients** | **Age, median (IQR), y** | **Sex (Male/Female)** | **Tumor location (head/ body or tail)** | **WHO performance status score (0+1/2)** |
| CRT | CT | CRT | CT | CRT | CT | CRT | CT | CRT | CT |
| Klassen DJ, 1985 | 47 | 44 | — | — | 22/25 | 31/13 | — | — | 35/12 | 37/7 |
| Gastrointestinal Tumor Study Group, 1988 | 22 | 21 | 61 | 60 | 14/8 | 13/8 | 19/3 | 18/3 | 20/2 | 18/3 |
| Chauffert B, 2008 | 59 | 60 | 60 | 62 | 31/28 | 34/26 | 46/13 | 40/20 | 54/5 | 46/14 |
| Loehrer PJ, 2011 | 34 | 37 | 66 (46.9–83.5) | 69 (49.7–83.7) | 19/15 | 18/19 | 20/9 | 25/5 | 34/0 | 37/0 |
| Hammel P, 2016 | 133 | 136 | 62.0 (55.0–70.0) | 63.0 (57.0–70.0) | 58/765 | 76/60 | 88/44 | 93/43 | 124/7 | 124/8 |

CRT = chemoradiotherapy, CT = chemotherapy.
5-fluorouracil (5-FU) and gemcitabine are potent radiosensitizers, and combined use of radiotherapy with 5-FU and gemcitabine has been shown to improve the survival of patients with locally advanced pancreatic cancer compared with radiotherapy alone. Gemcitabine and the oral fluoropyrimidine S-1 with IMRT for patients with LAPC is feasible and reduces toxicity, particularly nausea and vomiting. [19] Gemcitabine, oxaliplatin (GEMOX) and radiotherapy is feasible, and results in a high percentage of R0 resection, with encouraging outcome given the majority of patients with borderline resectable disease. [20] A capecitabine-based regimen is preferable to a gemcitabine-based counterpart in the context of consolidation CRT after a course of induction CT for LAPC. [21] With the introduction of active modern chemotherapeutic regimens, such as FOLFIRINOX (5-FU, leucovorin, irinotecan and oxaliplatin), [22] mFOLFIRINOX (no bolus 5-FU and a lower dose of irinotecan) [23] and gemcitabine plus nab-paclitaxel, [24] there has been a resurfing interest in the concept of converting unresectable or borderline resectable tumors to resectable ones.

The conclusions of this meta-analysis were limited by various factors. First, there was heterogeneity between study design, sample size, and the years covered. This may lead to false positives or false negatives, that is, risk of random errors. Secondly, the randomization procedure was unclear or inadequate in the assessed trials. [25] Funnel plots can be suggestive of publication bias with lack of negative small RCTs. However, a firm conclusion about bias was difficult to reach as the asymmetry of the funnel plot was minimal. In addition, funnel plots can show asymmetry for reasons other than publication bias. Therefore, the above pooled OR might be an overestimate of the true effect. Due to data constraints, this meta-analysis could not analyze the quality of life and progression-free survival rates, and was unable to carry out stratified analyses of other possible confounding factors. If the method is to be more effective, larger samples and randomized controlled studies with longer follow-up are required.

Furthermore, the included reports had different patient eligibility standards, evaluation times, initial treatment times, treatment programs, pathological types and progression-free survival criteria.

Advances in imaging have improved the diagnosis and staging of patients with pancreatic cancer, and neoadjuvant therapy has demonstrated promising early results; however, the prognosis of patients with LAPC remains poor. The following aspects may need further investigation. Additional imagining modalities are required to evaluate true response to treatment, to provide more

Table 4

| Variables | No. of studies furnishing data | CRT | CT | RR (95%CI) | P-value | I² |
|-----------|-------------------------------|-----|----|------------|---------|----|
| Overall survival |                               |     |    |            |         |    |
| 6 months   | 4 [8–10,12]                   | 90.73% | 89.37% | 1.13 [0.60–2.17] | .71 | 0% |
| 12 months  | 4 [8–10,12]                   | 54.03% | 54.72% | 1.15 [0.53–2.52] | .73 | 72% |
| 18 months  | 4 [8–10,12]                   | 28.23% | 31.50% | 1.13 [0.43–2.95] | .87 | 70% |
| 24 months  | 5 [7–10,12]                   | 14.92% | 13.76% | 1.07 [0.67–1.72] | .77 | 0% |
| Grade 3 to 4 adverse events |                        |     |    |            |         |    |
| Nausea, vomiting | 4 [8–10,12]          | 11.69% | 4.72% | 2.74 [1.36–5.52] | .005 | 45% |
| Diarrhea    | 4 [8–10,12]                   | 4.84% | 0.79% | 4.28 [1.16–15.71] | .03 | 0% |
| Chemotherapy included gemcitabine |                                 |     |    |            |         |    |
| 12 months   | 3 [9,10,12]                   | 54.87% | 57.94% | 0.91 [0.42–1.98] | .80 | 72% |
| 24 months   | 3 [9,10,12]                   | 16.81% | 16.31% | 1.03 [0.62–1.70] | .91 | 0% |
| Nausea, vomiting | 3 [9,10,12]          | 12.39% | 3.86% | 3.37 [1.50–7.56] | .003 | 0% |
| Small sample size |                               |     |    |            |         |    |
| 12 months   | 3 [8–10]                      | 40.87% | 41.53% | 1.34 [0.35–5.11] | .66 | 81% |
| 24 months   | 3 [8–10]                      | 11.11% | 10.49% | 1.08 [0.46–2.54] | .88 | 16% |
| Nausea, vomiting | 3 [8–10]                      | 20%   | 10.17% | 2.20 [1.05–4.62] | .04 | 51% |

CRT = chemoradiotherapy, CT = chemotherapy, LAPC = locally advanced pancreatic cancer.
accurate prognostic information and to guide optimal treatment. Novel tumor markers or other prognostic factors might also better guide therapeutic options, including assessing who might best benefit from surgical resection. Uniform inspection and judgment standards are also important. The resection rates should be a result of judgment indicators. Another important point is that treatment of LAPC requires a multidisciplinary team (radiologists, oncologists, surgeons, dietitians, and pathologists).

5. Conclusions
CRT was not superior to CT in the treatment of patients with LAPC, but had more complications. Further RCTs are warranted to clarify the exact values of CRT and CT for LAPC treatment.

Author contributions
Conceptualization: Cuiying Wang, Xiaohua Liu.
Data curation: Cuiying Wang, Xiaohua Wang, Yanlei Wang, Na Cha.
Formal analysis: Cuiying Wang, Xiaohua Liu, Xiaohua Wang, Yanlei Wang, Na Cha.
Project administration: Xiaohua Liu.
Writing – original draft: Cuiying Wang.
Writing – review & editing: Xiaohua Liu, Xiaohua Wang, Yanlei Wang, Na Cha.

References
[1] Breathwaite D, Demb J, Henderson LM, et al. American Cancer Society: Cancer Facts and Figures 2016. Atlanta, Ga:American Cancer Society; 2016.
[2] Mayahara H, Ito Y, Morizane C, et al. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. BMC Cancer 2012;12:609.
[3] Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71–96.
[4] Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:333–46, discussion 846–838.
[5] Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705–10.
[6] Hazell JJ, Thirlwell MP, Huggins M, et al. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 1981;32:164–5.
[7] Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373–8.
[8] Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751–5.
[9] Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592–9.
[10] Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011;29:4105–12.
[11] Lin GL, Zeng ZC, Zheng WU, et al. Regional intra-arterial chemotherapy with gemcitabine with or without 3-dimensional conformal radiotherapy for locally advanced pancreatic cancer. Chin Clin Oncol 2012;17:240–5.
Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 Randomized Clinical Trial. JAMA 2016;315:1844–53.

NCCN Guidelines, Pancreatic adenocarcinoma. Version 2.2018 (guidelines. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf).

Ben-Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;84:1166–71.

Yovino S, Maidment BW 3rd, Herman JM, et al. Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys 2012;83:916–20.

Rwigema JC, Heron DE, Parikh SD, et al. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. J Gastrointest Cancer 2012;43:70–6.

Comito T, Cozzi L, Clerici E, et al. Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study. Technol Cancer Res Treat 2016;16:1533034616659778.

Buwenge M, Cellini F, Silvestris N, et al. Robotic radiosurgery in pancreatic cancer: a systematic review. World J Gastroenterol 2015;21:9420–9.

Kennoki N, Nakayama H, Nagakawa Y, et al. Feasibility of intensity-modulated radiotherapy combined with gemcitabine and S-1 for patients with pancreatic cancer. Med Clin Oncol 2016;4:43–6.

Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013;119:2692–700.

Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multi-centre, randomised, phase 2 trial. Lancet Oncol 2013;14:317–26.

Gunturu KS, Yao X, Cong X, et al. FOLFRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013;30:361.

Katz MH, Shu Q, Ahmad SA, et al. Preoperative modified FOLFRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg 2016;151:e161137.

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–703.

Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601–5.